Foamix

Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office.

Foamix Ltd., a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office.

Foamix Ltd., a clinical-stage specialty pharmaceutical company has announced that the company has been granted a patent from Indian Patent Office # IN 249626 entitled “Foam Carrier Containing Amphiphilic Copolymeric Gelling Agent.”

Foamix’s first-in-class Minocycline Foam - now in phase II. Most Dermatologists are concerned with Oral Minocycline side effects and will prefer prescribing their patients Topical Minocycline for Rosacea, Acne, Skin Infections and Wounds.

Herzliya, Israel and Rehovot, Israel - Arkin Holdings and Foamix today announced that they have established a collaboration to develop and commercialize an innovative topical foam to treat patients with acne vulgaris and related disorders.